This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
VANCOUVER, British Columbia, July 03, 2018 (GLOBE NEWSWIRE) -- INTERFOR CORPORATION (“Interfor” or the “Company”) (TSX:IFP) will release its second quarter financial results on August 2, 2018. Information related to Interfor’s second quarter financial results will be available at www.interfor.com/investors.
NEW YORK, June 13 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX fell 23.16 points, or 0.14 percent, to 16,265.82. * The biggest weight to the TSX loss was Suncor Energy with a drag of 5.35 index points. In turn, energy weighed by 18.7 points on the index. * Leading the index were Aecon Group Inc, up 3.7 percent, NovaGold Resources Inc, up 3.7 percent, and Precision Drilling Corp , higher by 3.
IFSPF ACBFF IVN NG PDS CGC SU AEGXF IVPAF TWMJF ACB WEED BDRPF ARE PFSCF SU
VANCOUVER, British Columbia, May 22, 2018 (GLOBE NEWSWIRE) -- INTERFOR CORPORATION (“Interfor” or the “Company”) (TSX:IFP) announced today that it has resumed operations at its sawmill in Grand Forks, BC following severe flooding in the area over the past two weeks.
VANCOUVER, British Columbia, May 03, 2018 (GLOBE NEWSWIRE) -- INTERFOR CORPORATION (“Interfor” or the “Company”) (TSX:IFP) announced the voting results for the election of its Board of Directors, which took place at the Company’s Annual General Meeting held today in Vancouver, British Columbia. The nominees listed in the management information circular dated March 16, 2018, were elected as directors of the Company and detailed results of the votes cast by proxy are set out below:
April 19 (Reuters) - Canada’s main stock index was slightly lower on Thursday, as declines in financials and consumer cyclical companies weighed, but strong gains in energy shares that benefited from a rally in oil prices kept further losses in check.
ABX IFSPF ACBFF ABGLF TXCX TOLWF ACB ABGLY CNQ ACA ATHOF ATH ABX
VANCOUVER, British Columbia, April 18, 2018 (GLOBE NEWSWIRE) -- INTERFOR CORPORATION (“Interfor” or the “Company”) (TSX:IFP) announced today that it has removed the sale restrictions on, and consented to a sale by Ilim Timber Continental S.A. of, 3.68 million Interfor common shares in an ordinary market transaction.
VANCOUVER, British Columbia, April 03, 2018 (GLOBE NEWSWIRE) -- INTERFOR CORPORATION (“Interfor” or the “Company”) (TSX:IFP) will release its first quarter financial results on May 3, 2018. Information related to Interfor’s first quarter financial results will be available at www.interfor.com/investors.
April 3 (Reuters) - Canada’s main stock index fell on Tuesday as weakness in oil prices led to declines in energy stocks and dip in gold prices dragged the materials sector lower.
ACB IFSPF ACBFF PFSCF
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET